JP2014526513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526513A5 JP2014526513A5 JP2014530821A JP2014530821A JP2014526513A5 JP 2014526513 A5 JP2014526513 A5 JP 2014526513A5 JP 2014530821 A JP2014530821 A JP 2014530821A JP 2014530821 A JP2014530821 A JP 2014530821A JP 2014526513 A5 JP2014526513 A5 JP 2014526513A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- liver
- residue
- reduction
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 210000004185 Liver Anatomy 0.000 claims 8
- 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 claims 7
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-Galacturonic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- PNNNRSAQSRJVSB-BXKVDMCESA-N Rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 4
- 108090001123 antibodies Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- UNSKAUSCLTVFGO-KCDKBNATSA-N methyl (2S,3R,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoate Chemical compound COC(=O)[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O UNSKAUSCLTVFGO-KCDKBNATSA-N 0.000 claims 4
- 102000007563 Galectins Human genes 0.000 claims 3
- 108010046569 Galectins Proteins 0.000 claims 3
- 210000002966 Serum Anatomy 0.000 claims 3
- 238000009825 accumulation Methods 0.000 claims 3
- 239000003833 bile salt Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 201000004044 liver cirrhosis Diseases 0.000 claims 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 210000003494 Hepatocytes Anatomy 0.000 claims 2
- 208000008338 Non-alcoholic Fatty Liver Disease Diseases 0.000 claims 2
- 108009000135 Nonalcoholic fatty liver disease Proteins 0.000 claims 2
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 claims 2
- 230000001476 alcoholic Effects 0.000 claims 2
- 230000003078 antioxidant Effects 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 229920000140 heteropolymer Polymers 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N (2S,3S,4R,5S)-2,3,4,5-tetrahydroxyhexanal Chemical group C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 claims 1
- NIGNBCLEMMGDQP-UHFFFAOYSA-N 1-benzothiepine Chemical class S1C=CC=CC2=CC=CC=C12 NIGNBCLEMMGDQP-UHFFFAOYSA-N 0.000 claims 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 1
- BHQCQFFYRZLCQQ-UMZBRFQRSA-N 4-[(3R,5S,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CCC1(C)C1C2C2CCC(C(CCC(O)=O)C)C2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-UMZBRFQRSA-N 0.000 claims 1
- 229960004308 ACETYLCYSTEINE Drugs 0.000 claims 1
- 102100003659 APCS Human genes 0.000 claims 1
- 101710028063 APCS Proteins 0.000 claims 1
- 102000011690 Adiponectin Human genes 0.000 claims 1
- 108010076365 Adiponectin Proteins 0.000 claims 1
- 229940093761 Bile Salts Drugs 0.000 claims 1
- 208000008581 Brain Disease Diseases 0.000 claims 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N Coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 229940099500 Cystamine Drugs 0.000 claims 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N Cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 1
- 229940119025 Cysteamine Drugs 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229940009976 Deoxycholate Drugs 0.000 claims 1
- 206010014623 Encephalopathy Diseases 0.000 claims 1
- 206010014625 Encephalopathy Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 102000000802 Galectin 3 Human genes 0.000 claims 1
- 108010001517 Galectin 3 Proteins 0.000 claims 1
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 1
- LPLVUJXQOOQHMX-MYOOOWEVSA-N Glycyrrhizic acid Natural products O=C(O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](C(=O)O)O2)[C@@H](O[C@@H]2C(C)(C)[C@H]3[C@@](C)([C@H]4C(=O)C=C5[C@](C)([C@]4(C)CC3)CC[C@]3(C)[C@H]5C[C@](C(=O)O)(C)CC3)CC2)O1 LPLVUJXQOOQHMX-MYOOOWEVSA-N 0.000 claims 1
- 239000004378 Glycyrrhizin Substances 0.000 claims 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N HMG-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000006454 Hepatitis Diseases 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- 206010020578 Hyperbilirubinaemia Diseases 0.000 claims 1
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 229940067606 Lecithin Drugs 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 210000004698 Lymphocytes Anatomy 0.000 claims 1
- 229960003151 Mercaptamine Drugs 0.000 claims 1
- 210000000440 Neutrophils Anatomy 0.000 claims 1
- 108020005203 Oxidases Proteins 0.000 claims 1
- 102100004022 PTPRU Human genes 0.000 claims 1
- 101700071602 PTPRU Proteins 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 208000007232 Portal Hypertension Diseases 0.000 claims 1
- 210000003240 Portal Vein Anatomy 0.000 claims 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N Silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N Ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims 1
- 229960001661 Ursodiol Drugs 0.000 claims 1
- 229940046001 Vitamin B Complex Drugs 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 1
- 229940046009 Vitamin E Drugs 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 229960003487 Xylose Drugs 0.000 claims 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000692 anti-sense Effects 0.000 claims 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 201000004532 bilirubin metabolic disease Diseases 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 150000001747 carotenoids Chemical class 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 1
- 229960005188 collagen Drugs 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims 1
- 230000003247 decreasing Effects 0.000 claims 1
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229960003776 glatiramer acetate Drugs 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229960004949 glycyrrhizic acid Drugs 0.000 claims 1
- 235000019410 glycyrrhizin Nutrition 0.000 claims 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000002440 hepatic Effects 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 150000002515 isoflavone derivatives Chemical class 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 235000019136 lipoic acid Nutrition 0.000 claims 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003053 piperidines Chemical class 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 239000012268 protein inhibitor Substances 0.000 claims 1
- 229940121649 protein inhibitors Drugs 0.000 claims 1
- 238000001243 protein synthesis Methods 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims 1
- 239000002469 receptor inverse agonist Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 101700029010 rhiE Proteins 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
- 239000011669 selenium Substances 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- 235000017700 silymarin Nutrition 0.000 claims 1
- 229960004245 silymarin Drugs 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- -1 sisandra Substances 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 235000019529 tetraterpenoid Nutrition 0.000 claims 1
- 229960002663 thioctic acid Drugs 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- 230000014616 translation Effects 0.000 claims 1
- 229940115889 ursodeoxycholic acid Drugs 0.000 claims 1
- 235000019156 vitamin B Nutrition 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 150000003712 vitamin E derivatives Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000002076 α-tocopherol Substances 0.000 claims 1
- 235000004835 α-tocopherol Nutrition 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
Claims (14)
- 脂肪肝、非アルコール性脂肪肝疾患、非アルコール性脂肪性肝炎、肝線維症を伴う非アルコール性脂肪性肝炎、肝硬変を伴う非アルコール性脂肪性肝炎、または肝硬変および肝細胞癌を伴う非アルコール性脂肪性肝炎を処置するための、ガラクト−ラムノガラクツロネートを有効成分として含有する医薬組成物。
- 薬学的に許容される担体中にガラクト−ラムノガラクツロネートを含有する、請求項1に記載の組成物。
- 他の処置剤をさらに含有するか、または有効量の他の処置剤と併せて投与される、請求項1または2に記載の組成物。
- 非経口または経腸投与され、非アルコール性脂肪肝疾患または非アルコール性脂肪性肝炎評点システムの重篤度の少なくとも1ポイントの低下、非アルコール性脂肪性肝炎活動性の血清マーカーレベルの低下、非アルコール性脂肪性肝炎疾患活動性の低下、または非アルコール性脂肪性肝炎の医学的結果の軽減、の少なくとも1つを達成する、請求項1〜3のいずれかに記載の組成物。
- 肝臓における脂肪の蓄積の少なくとも10%の減少;
肝臓における脂肪を含む肝細胞の割合において評価される、肝臓における脂肪の蓄積の減少;
肝細胞風船化の少なくとも10%の軽減;
肝臓標本の門脈、中心および小葉域における好中球およびリンパ球の浸潤の少なくとも10%の軽減;
肝臓におけるコラーゲンの蓄積の少なくとも5%の減少;
肝組織または血清中のガレクチン−3の少なくとも10%の減少、
の1つを達成する、請求項4に記載の組成物。 - 非アルコール性脂肪性肝炎活動性の血清マーカーが、トランスアミナーゼ、還元型もしくは酸化型コエンザイムQ、またはそれらの組み合わせからなる群から選択される、請求項4に記載の組成物。
- 肝線維症または肝硬変を伴う非アルコール性脂肪性肝炎の医学的結果の軽減が、門脈圧亢進、肝タンパク質合成能低下、高ビリルビン血症、または脳障害の軽減を包含する、請求項4〜6のいずれかに記載の組成物。
- ガラクト−ラムノガラクツロネートが、α−1,2−結合ラムノースおよびα−1,4−結合GalA残基の交互オリゴマーである分岐へテロポリマーを結合する、1,4−結合ガラクツロン酸(GalA)およびメチルガラクツロネート(MeGalA)残基の主鎖を含み、前記ラムノース残基は1,4−β−D−ガラクトース残基、1,5−α−L−アラビノース残基またはそれらの組み合わせのオリゴマーである主な分岐を有する、ガラクトアラビノ−ラムノガラクツロネートである、請求項1〜7のいずれかに記載の組成物。
- ガラクト−ラムノガラクツロネートが、α−1,2−結合ラムノースおよびα−1,4−結合GalA残基の交互オリゴマーである分岐へテロポリマーを結合する、1,4−結合ガラクツロン酸(GalA)およびメチルガラクツロネート(MeGalA)残基の主鎖を含み、前記ラムノース残基は1,4−β−D−ガラクトース残基のオリゴマーである主な分岐を有する、請求項1〜7のいずれかに記載の組成物。
- 1,4−β−D−ガラクトース残基と1,5−α−L−アラビノース残基が、2:1または3:1の比で存在し;および/または
1,4−β−D−ガラクトース残基、1,5−α−L−アラビノース残基またはそれらの組み合わせが、炭水化物の総モルの少なくとも10モル%の量で存在する、
請求項8に記載の組成物。 - ガラクト−ラムノガラクツロネートが、5〜55kDaの範囲、2〜80kDaの範囲、または20〜70kDaの範囲の平均分子量を有する、請求項1〜10のいずれかに記載の組成物。
- 他の処置剤が、システアミンもしくはその薬学的に許容される塩、シスタミンもしくはその薬学的に許容される塩、抗酸化化合物、レシチン、ビタミンB複合体、胆汁塩製剤、カンナビノイド−1(CB1)受容体アンタゴニスト、カンナビノイド−1(CB1)受容体インバースアゴニスト、ペルオキシソーム増殖剤活性化受容体活性調節剤、ベンゾチアゼピンもしくはベンゾチエピン化合物、タンパク質チロシンホスファターゼPTPRUを阻害するRNAアンチセンス構築物、ヘテロ原子結合置換ピペリジンおよびその誘導体、アザシクロペンタン誘導体、アディポネクチン分泌促進または誘導活性を有するアシルアミド化合物、第四級アンモニウム化合物、グラチラマーアセテート、ペントラキシンタンパク質、HMG−CoAレダクターゼ阻害剤、N−アセチルシステイン、イソフラボン化合物、マクロライド抗生物質、ガレクチン阻害剤、抗体、またはそれらの組み合わせ、の1つである、請求項3に記載の組成物。
- 抗酸化化合物が、水溶性ビタミンE製剤、カロテノイド混合物、セレン、グリチルリチン、シサンドラ、アスコルビン酸、L−グルタチオン、シリマリン、リポ酸またはd−α−トコフェロール、またはそれらの組み合わせを含み;
胆汁塩製剤が、ウルソデオキシコール酸、ケノデオキシコール酸または他の天然もしくは合成胆汁酸または胆汁酸塩、またはそれらの組み合わせを含み;
ペントラキシンタンパク質が、組換えペントラキシン−2であり;
HMG−CoAレダクターゼ阻害剤が、アトルバスタチン、シンバスタチンまたはそれらの組み合わせを含み;
ガレクチン阻害剤が、小有機ガレクチン阻害剤、モノクローナル抗体、RNA阻害剤、小結合ペプチド、タンパク質阻害剤、またはそれらの組み合わせを含み;または
抗体が、抗リシルオキシダーゼ抗体、または抗結合組織増殖因子抗体である、
請求項12に記載の組成物。 - ガラクト−ラムノガラクツロネートが、キシロース、グルコース、フコース残基またはそれらの組み合わせをさらに含む、請求項1〜13のいずれかに記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161535655P | 2011-09-16 | 2011-09-16 | |
US61/535,655 | 2011-09-16 | ||
US201261656288P | 2012-06-06 | 2012-06-06 | |
US61/656,288 | 2012-06-06 | ||
PCT/US2012/055360 WO2013040324A1 (en) | 2011-09-16 | 2012-09-14 | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014526513A JP2014526513A (ja) | 2014-10-06 |
JP2014526513A5 true JP2014526513A5 (ja) | 2015-11-12 |
JP6185473B2 JP6185473B2 (ja) | 2017-08-23 |
Family
ID=47883762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014530821A Active JP6185473B2 (ja) | 2011-09-16 | 2012-09-14 | 非アルコール性脂肪性肝炎および非アルコール性脂肪肝疾患を処置するためのガラクト−ラムノガラクツロネート組成物 |
Country Status (12)
Country | Link |
---|---|
US (2) | US8658787B2 (ja) |
EP (1) | EP2755480B1 (ja) |
JP (1) | JP6185473B2 (ja) |
KR (1) | KR101974675B1 (ja) |
CN (1) | CN103945695B (ja) |
AU (1) | AU2012308491B2 (ja) |
BR (1) | BR112014006220A2 (ja) |
CA (1) | CA2848711C (ja) |
ES (1) | ES2869884T3 (ja) |
IL (1) | IL231512B (ja) |
MX (1) | MX360979B (ja) |
WO (2) | WO2013040324A1 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008011216A2 (en) * | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
CN104245717B (zh) | 2011-12-28 | 2017-10-24 | 卡莱克汀医疗有限公司 | 用于治疗人类疾病的新型糖类药物的组合物 |
CN104619329B (zh) | 2012-06-06 | 2018-01-26 | 卡莱克汀医疗有限公司 | 用于治疗与升高的诱导型一氧化氮合酶相关联的疾病的半乳糖‑鼠李糖半乳糖醛酸酯组合物 |
DK2900061T3 (da) * | 2012-09-17 | 2020-03-02 | Galectin Therapeutics Inc | Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling |
CA2924597A1 (en) * | 2013-09-19 | 2015-03-26 | The Research Foundation For The State University Of New York | Methods and materials for treating diabetes or liver steatosis |
CN106714812A (zh) * | 2014-03-10 | 2017-05-24 | 拉卓拉药物公司 | 用于治疗肾病的组合物和方法 |
JP2017525702A (ja) * | 2014-08-18 | 2017-09-07 | ファーマジェネシス, インコーポレイテッド | ポリガラクツロナンラムノガラクツロナン(pgrg1)組成物 |
MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
US20180050078A1 (en) * | 2015-03-03 | 2018-02-22 | KOHJIN Life Sciences Co., Ltd. | Composition for improving or preventing nonalcoholic fatty liver |
WO2016160594A1 (en) | 2015-03-27 | 2016-10-06 | The Research Foundation For The State University Of New York | Methods and materials for reducing amyloid beta levels within a mammal |
JP7068827B2 (ja) * | 2015-06-30 | 2022-05-17 | アイガー グループ インターナショナル インコーポレイテッド | 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用 |
EP3393494A1 (en) * | 2015-12-22 | 2018-10-31 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
BR112018067693A2 (pt) * | 2016-03-04 | 2019-01-08 | Galectin Sciences Llc | compostos de selenogalactosídeo para a prevenção e tratamento de doenças associadas com galectina e usos dos mesmos |
FR3050112B1 (fr) | 2016-04-15 | 2020-09-04 | Soc Civ Immobiliere Gecinq | Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques |
KR102444366B1 (ko) * | 2016-06-03 | 2022-09-19 | 케모센트릭스, 인크. | 간 섬유화 치료 방법 |
US10342785B2 (en) * | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
MX2019012086A (es) | 2017-04-14 | 2021-01-08 | Gelesis Llc | Composiciones y métodos para tratar o prevenir trastornos relacionados con la permeabilidad intestinal. |
WO2018209255A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
WO2019010024A1 (en) * | 2017-07-04 | 2019-01-10 | The Regents Of The University Of California | METHODS OF TREATING LIVER DISEASES ASSOCIATED WITH INFLAMMATION OF DOOR SPACE OR PERIODAL INFLAMMATION |
CN111183360A (zh) * | 2017-07-19 | 2020-05-19 | 生物辐射欧洲有限公司 | 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合 |
GB201804922D0 (en) * | 2018-03-27 | 2018-05-09 | Ucl Business Plc | Traatment |
CN112672765A (zh) | 2018-06-29 | 2021-04-16 | 格莱科斯生物医药公司 | 结合物 |
WO2021123506A1 (en) | 2019-12-18 | 2021-06-24 | Glykos Biomedical Oy | Stabile conjugate |
MX2022014575A (es) * | 2020-05-22 | 2022-12-15 | Durect Corp | Tratamiento para la esteatohepatitis no alcoholica (nash). |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4011285A1 (de) * | 1990-04-06 | 1991-10-10 | Steigerwald Arzneimittelwerk | Arzneimittel zur behandlung von hyperlipidaemie und/oder atherosklerose |
US6297229B1 (en) | 1994-11-14 | 2001-10-02 | Mayo Foundation For Medical Education And Research | Use of ursodeoxycholic acid to treat nonalcoholic steatohepatitis |
US5760010A (en) | 1995-01-01 | 1998-06-02 | Klein; Ira | Method of treating liver disorders with a macrolide antibiotic |
US6180139B1 (en) | 1998-12-04 | 2001-01-30 | Viva America Marketing, Inc. | Composition and method for treating nonalcoholic steatohepatitis |
WO2000062076A1 (en) * | 1999-04-13 | 2000-10-19 | Hsu Daniel K | Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma |
WO2000062774A1 (en) | 1999-04-20 | 2000-10-26 | Board Of Trustees, Southern Illinois University | Methods of treating clinical diseases with isoflavones |
CN1142272C (zh) * | 2000-02-02 | 2004-03-17 | 中国人民解放军军事医学科学院百环生物医学研究中心 | 携带人肝细胞生长因子基因的重组腺病毒的用途 |
CA2406930C (en) * | 2000-02-04 | 2011-02-15 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
US6596762B2 (en) | 2001-05-17 | 2003-07-22 | The Regents Of The University Of Colorado | Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis |
PL367415A1 (en) * | 2001-07-20 | 2005-02-21 | Intermune, Inc. | Methods of treating liver fibrosis |
US7312208B2 (en) | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
US20040223971A1 (en) | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
US7078064B2 (en) | 2003-12-03 | 2006-07-18 | George Zabrecky | Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
KR20070026392A (ko) | 2004-02-27 | 2007-03-08 | 아사히 가세이 파마 가부시키가이샤 | 신규 벤조티아제핀 및 벤조티에핀 화합물 |
EP1765874A1 (en) * | 2004-03-26 | 2007-03-28 | Glycogenesys, Inc. | Modified pectins, compositions and methods related thereto |
JP2008105945A (ja) | 2005-02-07 | 2008-05-08 | Ajinomoto Co Inc | アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物 |
EP1924294A4 (en) | 2005-05-24 | 2010-11-03 | Isis Pharmaceuticals Inc | COMPOSITIONS AND USES FOR MODULATING EXPRESSION OF PTPRU |
MX2007014501A (es) * | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos novedosos que contienen acido fosfinico. |
KR20080021082A (ko) | 2005-06-20 | 2008-03-06 | 쉐링 코포레이션 | 히스타민 h3 길항제로서 유용한 피페리딘 유도체 |
WO2007016390A1 (en) * | 2005-07-28 | 2007-02-08 | Children's Medical Center Corporation | Matrix metalloproteinase inhibitors for treating fatty liver disease |
US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
WO2008011216A2 (en) * | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
JP5105297B2 (ja) | 2006-05-25 | 2012-12-26 | 味の素株式会社 | Ppar活性調節剤 |
AU2007260528A1 (en) | 2006-06-13 | 2007-12-21 | Merck Frosst Canada Ltd. | Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
US20080194575A1 (en) * | 2006-10-04 | 2008-08-14 | Naiara Beraza | Treatment for non-alcoholic-steatohepatitis |
US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
MX360827B (es) * | 2007-11-30 | 2018-11-16 | Univ California | Metodos para tratar la esteatohepatitis no alcoholica (nash) usando productos de cisteamina. |
MX2010007426A (es) * | 2008-01-31 | 2010-08-18 | Astellas Pharma Inc | Composiciones farmaceuticas para tratar trastorno del higado graso. |
EP2260305A1 (en) * | 2008-03-27 | 2010-12-15 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Methods and kits for determining the occurrence of a liver disease in a subject |
US20110082119A1 (en) | 2008-06-13 | 2011-04-07 | Takashi Yano | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
US20110313276A1 (en) * | 2008-11-18 | 2011-12-22 | Centre Hospitalier Universitaire D'angers | Non-invasive in vitro method for quantifying liver lesions |
JP2010229099A (ja) * | 2009-03-27 | 2010-10-14 | Mochida Pharmaceut Co Ltd | 脂質異常症の改善または治療薬 |
WO2011088404A1 (en) * | 2010-01-15 | 2011-07-21 | Infinity Pharmaceuticals , Inc | Treatment of fibrotic conditions using hedgehog inhibitors |
CN104245717B (zh) * | 2011-12-28 | 2017-10-24 | 卡莱克汀医疗有限公司 | 用于治疗人类疾病的新型糖类药物的组合物 |
-
2012
- 2012-09-14 MX MX2014003213A patent/MX360979B/es active IP Right Grant
- 2012-09-14 WO PCT/US2012/055360 patent/WO2013040324A1/en active Application Filing
- 2012-09-14 AU AU2012308491A patent/AU2012308491B2/en active Active
- 2012-09-14 EP EP12831657.7A patent/EP2755480B1/en active Active
- 2012-09-14 CN CN201280049079.6A patent/CN103945695B/zh active Active
- 2012-09-14 JP JP2014530821A patent/JP6185473B2/ja active Active
- 2012-09-14 WO PCT/US2012/055348 patent/WO2013040316A1/en active Application Filing
- 2012-09-14 ES ES12831657T patent/ES2869884T3/es active Active
- 2012-09-14 KR KR1020147009796A patent/KR101974675B1/ko active IP Right Grant
- 2012-09-14 US US13/573,454 patent/US8658787B2/en active Active
- 2012-09-14 BR BR112014006220A patent/BR112014006220A2/pt not_active Application Discontinuation
- 2012-09-14 US US13/573,436 patent/US20130259870A1/en not_active Abandoned
- 2012-09-14 CA CA2848711A patent/CA2848711C/en active Active
-
2014
- 2014-03-13 IL IL231512A patent/IL231512B/en active IP Right Grant
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014526513A5 (ja) | ||
Oh et al. | Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling | |
Lee et al. | The use of low molecular weight heparin–pluronic nanogels to impede liver fibrosis by inhibition the TGF-β/Smad signaling pathway | |
ES2877326T3 (es) | Composiciones que comprenden un sulforafano y extracto o polvo de cardo mariano | |
JP2015522561A5 (ja) | ||
ES2848538T3 (es) | Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible | |
ES2871783T3 (es) | Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas | |
EP3307265B1 (en) | Pharmaceutical combination and uses thereof | |
EP3937925A1 (en) | Cannabinoid acid ester compositions and uses thereof | |
JP2009530398A5 (ja) | ||
Zhang et al. | Reversing the imbalance in bone homeostasis via sustained release of SIRT-1 agonist to promote bone healing under osteoporotic condition | |
Xu et al. | Sialic acid-modified chitosan oligosaccharide-based biphasic calcium phosphate promote synergetic bone formation in rheumatoid arthritis therapy | |
EP2392335B1 (en) | Use of 24-norUDCA | |
Lee et al. | Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate | |
WO2013059879A1 (en) | Compositions and methods for the treatment of fibrosis and fibrotic diseases | |
KR102187681B1 (ko) | 히알루론산 나노입자를 함유하는 섬유증의 예방 또는 치료용 약학 조성물 | |
RU2491065C2 (ru) | Фармацевтическая композиция, содержащая производное 1,2-дитиолтиона, для предотвращения или лечения заболевания, обусловленного повышенной экспрессией lxr-альфа | |
US20220331392A1 (en) | Larazotide formulations | |
Cüre et al. | Topiramate has protective effect on renal injury | |
CN114341148B (zh) | 抗衰老和抗炎前药及其使用方法 | |
JP2020516622A (ja) | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 | |
WO2003074084A1 (en) | A pharmaceutical composition | |
JP2013515049A5 (ja) | ||
WO2010123769A1 (en) | Compositions and methods for treating ocular inflammation with lower risk of increased intraocular pressure | |
CN115361942A (zh) | 药物组合物及其抑制膜ace2表达的用途 |